These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24528069)

  • 1. IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
    Wang JB; Dong DF; Wang MD; Gao K
    Asian Pac J Cancer Prev; 2014; 15(1):427-32. PubMed ID: 24528069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
    Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
    Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
    Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
    Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
    Li MY; Yang P; Liu YW; Zhang CB; Wang KY; Wang YY; Yao K; Zhang W; Qiu XG; Li WB; Peng XX; Wang YZ; Jiang T
    Sci Rep; 2016 Feb; 6():21141. PubMed ID: 26879272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
    Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
    Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
    Tateishi K; Higuchi F; Miller JJ; Koerner MVA; Lelic N; Shankar GM; Tanaka S; Fisher DE; Batchelor TT; Iafrate AJ; Wakimoto H; Chi AS; Cahill DP
    Cancer Res; 2017 Aug; 77(15):4102-4115. PubMed ID: 28625978
    [No Abstract]   [Full Text] [Related]  

  • 9. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
    Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
    Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
    Ohba S; Mukherjee J; See WL; Pieper RO
    Cancer Res; 2014 Sep; 74(17):4836-44. PubMed ID: 25035396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
    Lu Y; Kwintkiewicz J; Liu Y; Tech K; Frady LN; Su YT; Bautista W; Moon SI; MacDonald J; Ewend MG; Gilbert MR; Yang C; Wu J
    Cancer Res; 2017 Apr; 77(7):1709-1718. PubMed ID: 28202508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
    Shi J; Sun B; Shi W; Zuo H; Cui D; Ni L; Chen J
    Tumour Biol; 2015 Feb; 36(2):655-62. PubMed ID: 25283382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
    Jaime-Ramirez AC; Dmitrieva N; Yoo JY; Banasavadi-Siddegowda Y; Zhang J; Relation T; Bolyard C; Wojton J; Kaur B
    J Gene Med; 2017 Mar; 19(3):. PubMed ID: 28087981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
    Kong DS; Kim HR; Choi YR; Seol HJ; Lee JI; Nam DH
    J Clin Neurosci; 2015 Sep; 22(9):1425-9. PubMed ID: 26138051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
    Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
    Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
    Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
    Sun X; Turcan S
    Cells; 2021 May; 10(5):. PubMed ID: 34067729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
    Koncar RF; Chu Z; Romick-Rosendale LE; Wells SI; Chan TA; Qi X; Bahassi EM
    Oncotarget; 2017 Feb; 8(9):15827-15837. PubMed ID: 28178660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.